Journal: Bioactive Materials

Article Title: Sulfated liposome-based artificial cell membrane glycocalyx nanodecoys for coronavirus inactivation by membrane fusion

doi: 10.1016/j.bioactmat.2023.10.021

Figure Lengend Snippet: Nanodecoy membrane fusion causes virus block. The cryo-TEM image of (A) SARS-CoV-2 or (B) SARS-CoV-2 incubated with 40S_Lip. The arrow pointing the spike protein. Scale bar: 50 nm. (C) The membrane fusion profile of the FRET lipid labeled nanodecoy 40S_Lip(FRET) incubated with no FRET lipid labeled nanodecoy 40S_Lip, SARS-CoV-2 pseudovirus, or 40S_Lip and SARS-CoV-2 pseudovirus. (D) The MD simulation result of the spike protein incubated with 40S_Lip for 0, 0.12, and 2 ns. (E) The potential of mean force curves for 40S_Lip and S protein. (F) The CD spectrum of the native spike protein or when incubated with 40S_Lip. (G) The percentage of the detected free spike protein after incubation with heparin, 40S_Lip(Large), or 40S_Lip. (H) The percentage of the detected spike protein on the SARS-CoV-2 pseudovirus after incubation with heparin, 40S_Lip(Large), or 40S_Lip.

Article Snippet: The SARS-CoV-2 spike protein S1 RBD ELISA kit was purchased from Elabscience Biotechnology Co., Ltd. (Wuhan, China).

Techniques: Membrane, Virus, Blocking Assay, Incubation, Labeling

Journal: Oxidative Medicine and Cellular Longevity

Article Title: RBM10 Is a Biomarker Associated with Pan-Cancer Prognosis and Immune Infiltration: System Analysis Combined with In Vitro and Vivo Experiments

doi: 10.1155/2022/7654937

Figure Lengend Snippet: Pan-cancer analysis of the RBM10 expression. (a) RBM10 mRNA expression levels in different cancers and normal tissues of TCGA and GTEx databases. (b) RBM10 mRNA levels in tumor and normal tissues for 22 cancers of TCGA. (c) The expression levels of RBM10 mRNA in different primary tumors, metastatic tumors, and corresponding normal tissues were assessed according to TNM plotter website. (d) The correlation between RBM10 expression and the pathological stages of cancers using GEPIA. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001. -: not significant.

Article Snippet: The primarily antibodies were used: PD-L1 (dilution, 1 : 2000, Cat. No. 66248-1-Ig, Proteintech, Wuhan, China), RBM10 (dilution, 1 : 1000, Cat. No. 14423-1-AP, Proteintech, Wuhan, China), and β -actin (dilution, 1 : 50000, Cat. No. 66009-1-Ig, Proteintech, Wuhan, China).

Techniques: Expressing

Journal: Oxidative Medicine and Cellular Longevity

Article Title: RBM10 Is a Biomarker Associated with Pan-Cancer Prognosis and Immune Infiltration: System Analysis Combined with In Vitro and Vivo Experiments

doi: 10.1155/2022/7654937

Figure Lengend Snippet: The prognosis value of RBM10 in human tumors. The median RBM10 expression was taken as the cut-off value. (a) The survival heat map represented the relationship between RBM10 expression and overall survive (OS) in TCGA tumors by using GEPIA2 tool. The survival curves showed the significant differences correlation of the RBM10 expression with OS of KIRP, MESO, PAAD, LIHC, and UVM. p < 0.05 was statistically significant. (b) The survival heat map represented the link of RBM10 level with disease-free survival (DFS) in TCGA tumor by GEPIA2 tool. The survival curves showed the significant difference correlation of the RBM10 expression with DFS of ACC, GBM, LIHC, UVM, KIRP, MESO, and PRAD. p < 0.05 was statistically significant.

Article Snippet: The primarily antibodies were used: PD-L1 (dilution, 1 : 2000, Cat. No. 66248-1-Ig, Proteintech, Wuhan, China), RBM10 (dilution, 1 : 1000, Cat. No. 14423-1-AP, Proteintech, Wuhan, China), and β -actin (dilution, 1 : 50000, Cat. No. 66009-1-Ig, Proteintech, Wuhan, China).

Techniques: Expressing

Journal: Oxidative Medicine and Cellular Longevity

Article Title: RBM10 Is a Biomarker Associated with Pan-Cancer Prognosis and Immune Infiltration: System Analysis Combined with In Vitro and Vivo Experiments

doi: 10.1155/2022/7654937

Figure Lengend Snippet: Mutation characteristics of RBM10. (a) Alteration frequency of RBM10 in different cancers was accessed by the cBioPortal website. (b) Mutation frequency of RBM10 from the TIMER2.0 database. (c) Different mutation sites of RBM10. (d) The relationship of RBM10 mutation status with OS, DFS, DSS, and PFS in all TCGA tumors. (e) The KM curve showed the association of RBM10 mutation status with OS of LUSC, PFS of PRAD, and OS of UCS, respectively. p < 0.05 was statistically significant.

Article Snippet: The primarily antibodies were used: PD-L1 (dilution, 1 : 2000, Cat. No. 66248-1-Ig, Proteintech, Wuhan, China), RBM10 (dilution, 1 : 1000, Cat. No. 14423-1-AP, Proteintech, Wuhan, China), and β -actin (dilution, 1 : 50000, Cat. No. 66009-1-Ig, Proteintech, Wuhan, China).

Techniques: Mutagenesis

Journal: Oxidative Medicine and Cellular Longevity

Article Title: RBM10 Is a Biomarker Associated with Pan-Cancer Prognosis and Immune Infiltration: System Analysis Combined with In Vitro and Vivo Experiments

doi: 10.1155/2022/7654937

Figure Lengend Snippet: RBM10 methylation level in pan-cancer. (a) Spearman's correlation of RBM10 methylation with the mRNA expression in various cancers. Blue bubbles represent negative correlation. The darker the color, the higher the correlation. Bubble size was positively correlated with FDR. Black outline indicates FDR < 0.05. (b) Scatter plots represented the top four tumors with the strongest correlations. (c) Prognostic analysis of RBM10 between hypermethylated and hypomethylated groups in different types of cancer. p < 0.05 was statistically significant.

Article Snippet: The primarily antibodies were used: PD-L1 (dilution, 1 : 2000, Cat. No. 66248-1-Ig, Proteintech, Wuhan, China), RBM10 (dilution, 1 : 1000, Cat. No. 14423-1-AP, Proteintech, Wuhan, China), and β -actin (dilution, 1 : 50000, Cat. No. 66009-1-Ig, Proteintech, Wuhan, China).

Techniques: Methylation, Expressing

Journal: Oxidative Medicine and Cellular Longevity

Article Title: RBM10 Is a Biomarker Associated with Pan-Cancer Prognosis and Immune Infiltration: System Analysis Combined with In Vitro and Vivo Experiments

doi: 10.1155/2022/7654937

Figure Lengend Snippet: The association of the RBM10 expression with immune cell infiltration level in pan-cancer. (a) A heat map of the relationship between RBM10 expression and levels of immune cell infiltration in human cancer types was obtained using TIMER2. (b) A heat map of the correlation between RBM10 and levels of immune cell infiltration in 33 cancers was drawn using xCell. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Article Snippet: The primarily antibodies were used: PD-L1 (dilution, 1 : 2000, Cat. No. 66248-1-Ig, Proteintech, Wuhan, China), RBM10 (dilution, 1 : 1000, Cat. No. 14423-1-AP, Proteintech, Wuhan, China), and β -actin (dilution, 1 : 50000, Cat. No. 66009-1-Ig, Proteintech, Wuhan, China).

Techniques: Expressing

Journal: Oxidative Medicine and Cellular Longevity

Article Title: RBM10 Is a Biomarker Associated with Pan-Cancer Prognosis and Immune Infiltration: System Analysis Combined with In Vitro and Vivo Experiments

doi: 10.1155/2022/7654937

Figure Lengend Snippet: Relationship between RBM10 expression and tumor mutation burden (TMB), microsatellite instability (MSI), mismatch repairs (MMRs), neoantigens, immune checkpoint (ICP) genes, and some immune-related pathway. (a) Radar map of the correlation between RBM10 expression and TMB. (b) Radar map showed the association between RBM10 expression and MSI. (c) A heat map indicated the correlation of the RBM10 expression with the expression of MMR genes. The lower triangle of each square represented Spearman's correlation coefficient, and the upper triangle represented the p value. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001. (d) The heat map showed the association of RBM10 with ICP genes in pan-cancer using TCGA data from SangerBox. The upper triangle of each square represented the p value of correlation test, and the lower triangle represented Spearman's correlation coefficient. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001. (e) Heat map of the correlation between RBM10 expression and some immune-related pathway. The upper triangle of each square represented the p value of correlation test, and the lower triangle represented Spearman's correlation coefficient. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Article Snippet: The primarily antibodies were used: PD-L1 (dilution, 1 : 2000, Cat. No. 66248-1-Ig, Proteintech, Wuhan, China), RBM10 (dilution, 1 : 1000, Cat. No. 14423-1-AP, Proteintech, Wuhan, China), and β -actin (dilution, 1 : 50000, Cat. No. 66009-1-Ig, Proteintech, Wuhan, China).

Techniques: Expressing, Mutagenesis, Immunopeptidomics

Journal: Oxidative Medicine and Cellular Longevity

Article Title: RBM10 Is a Biomarker Associated with Pan-Cancer Prognosis and Immune Infiltration: System Analysis Combined with In Vitro and Vivo Experiments

doi: 10.1155/2022/7654937

Figure Lengend Snippet: Enrichment analysis of RBM10. (a) The RBM10 interacting proteins were obtained using STRING tool. (b) Top 50 RBM10-related genes were explored through GEPIA2, and we selected top 10 genes (CCDC22, DHX30, HDGFRP2, HNRNPA0, ILF3, MLLTT1, SAFB, SF4, SRRT, and UBTF). A heat map indicated the correlation of the RBM10 expression with the expression of selected target genes in pan-cancer by using TIMER2.0. (c) The correlation between RBM10 expression and the selected 10 target genes using GEPIA2. (d) Enrichment analysis of RBM10 in KEGG and HALLMARK pathways.

Article Snippet: The primarily antibodies were used: PD-L1 (dilution, 1 : 2000, Cat. No. 66248-1-Ig, Proteintech, Wuhan, China), RBM10 (dilution, 1 : 1000, Cat. No. 14423-1-AP, Proteintech, Wuhan, China), and β -actin (dilution, 1 : 50000, Cat. No. 66009-1-Ig, Proteintech, Wuhan, China).

Techniques: Expressing

Journal: Oxidative Medicine and Cellular Longevity

Article Title: RBM10 Is a Biomarker Associated with Pan-Cancer Prognosis and Immune Infiltration: System Analysis Combined with In Vitro and Vivo Experiments

doi: 10.1155/2022/7654937

Figure Lengend Snippet: RBM10 inhibited the proliferation, migration, and invasion of LUAD cells and affects the protein stability of PD-L1 in vitro . After effectively upregulating or silencing the RBM10 expression in H3255 and H827 cells, (a, b) CCK-8 assays were performed to assess proliferation of LUAD cells. (c) The colony formation assays were used to measure cell clonalities. (d, e) Transwell assays were used to examine cell invasiveness and migration capability; scale bar, 100 μ m. (f, g) After silencing (f) or overexpressing (g) RBM10 in LUAD cells, western blot examined the protein level of PD-L1. (h, i) After cycloheximide (CHX, 20 μ g/ml) treated H3255 (h) and H827 (i) cells with stably overexpressing RBM10 for 0, 2, 4, 6, and 8 hours, western blot analyzed the protein stability of PD-L1. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Article Snippet: The primarily antibodies were used: PD-L1 (dilution, 1 : 2000, Cat. No. 66248-1-Ig, Proteintech, Wuhan, China), RBM10 (dilution, 1 : 1000, Cat. No. 14423-1-AP, Proteintech, Wuhan, China), and β -actin (dilution, 1 : 50000, Cat. No. 66009-1-Ig, Proteintech, Wuhan, China).

Techniques: Migration, In Vitro, Expressing, CCK-8 Assay, Western Blot, Stable Transfection

Journal: Oxidative Medicine and Cellular Longevity

Article Title: RBM10 Is a Biomarker Associated with Pan-Cancer Prognosis and Immune Infiltration: System Analysis Combined with In Vitro and Vivo Experiments

doi: 10.1155/2022/7654937

Figure Lengend Snippet: Overexpression of RBM10 inhibited LUAD tumor growth in vivo . (a) The model of subcutaneous transplanted tumor was established by subcutaneous injection of stable RBM10 overexpression groups (H3255-RBM10) and control groups (H3255-vector) into axilla of nude mice. (b) The xenograft tumor growth curves of the H3255-RBM10 and H3255-vector groups. (c) After the mice were sacrificed on day 35, we presented the representative images of the subcutaneous xenograft tumor lumps from the H3255-vector and H3255-RBM10 groups. (d) Representative images of IHC of Ki67, PD-L1, and RBM10 in nude mice xenograft tumor sections were shown (magnification, ×400; scale bar, 20 μ m). (e) The protein levels of PD-L1 and RBM10 in xenograft tumor tissues were detected by western blot. β -Actin was used as an internal control. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Article Snippet: The primarily antibodies were used: PD-L1 (dilution, 1 : 2000, Cat. No. 66248-1-Ig, Proteintech, Wuhan, China), RBM10 (dilution, 1 : 1000, Cat. No. 14423-1-AP, Proteintech, Wuhan, China), and β -actin (dilution, 1 : 50000, Cat. No. 66009-1-Ig, Proteintech, Wuhan, China).

Techniques: Over Expression, In Vivo, Injection, Control, Plasmid Preparation, Western Blot

Journal: Nucleic Acids Research

Article Title: COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics

doi: 10.1093/nar/gkaa969

Figure Lengend Snippet: COVID19-specific collections and chemical libraries

Article Snippet: MedChemExpress , SARS-CoV List of Drugs , 76 , https://www.medchemexpress.com/Targets/SARS-CoV.html.

Techniques: Protein-Protein interactions, Drug discovery